Kyttaro’s patent portfolio was developed by the scientific team at Apceth Biopharma GmbH (established in 2007 and operations sold to Hitachi Chemical in 2019).
In 2019, Apceth Biopharma GmbH licensed its patent portfolio to JuntuCell GmbH.
In 2021, Kyttaro Therapeutics was incorporated in the United States to commercialize this unique patent portfolio. Juntucell GmbH granted Kyttaro Therapeutics the worldwide, exclusive license to 61 patents together with all know-how, for applications of MSC-AAT, MSC-Cytokine and MSC-Klotho.
Kyttaro Therapeutics is poised to commence clinical trials in Europe and the US for GvHD applications, with others to follow. We are seeking clinical partners in the US both to produce MSC-AAT and to engage in clinical trials with us.
We invite interested partners to contact us for more details.
Academic Partnerships Under Discussion
Initial Partnerships
WilmerHale is a leading, full-service international law firm with 1,000 lawyers located throughout 13 offices in the United States, Europe and Asia. WilmerHale ranks amongst the top law firms for its work in the are of Venture Capital and Emerging Companies. They serve as Kyttaro’s corporate lawyers and intellectual property in the US.
Parexel is one of the worlds leading global clinical research organizations (CRO) and our initial partner for clinical trials management. Over the past five years, Parexel has provided regulatory, clinical and technology project services for around 20 regenerative medicine projects and more than 250 cell therapy, gene therapy and stem cell therapy projects.
HERTIN & Partner is a law firm focused on the protection of inventions, creative activities, trademarks and freedom of action in competitive marketplaces in Germany and beyond. They have served as patent counsel on Kyttaro’s patent portfolio since the inception of the technology.